NO934653L - Use of thrombin inhibitors for inhibition of ocular fibrin formation - Google Patents

Use of thrombin inhibitors for inhibition of ocular fibrin formation

Info

Publication number
NO934653L
NO934653L NO934653A NO934653A NO934653L NO 934653 L NO934653 L NO 934653L NO 934653 A NO934653 A NO 934653A NO 934653 A NO934653 A NO 934653A NO 934653 L NO934653 L NO 934653L
Authority
NO
Norway
Prior art keywords
inhibition
thrombin inhibitors
fibrin formation
ocular
ocular fibrin
Prior art date
Application number
NO934653A
Other languages
Norwegian (no)
Inventor
Jurgen Romisch
Eric Paul Paques
Eckhard Schuler
Original Assignee
Behringswerke Aktiengelschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringswerke Aktiengelschaft filed Critical Behringswerke Aktiengelschaft
Publication of NO934653L publication Critical patent/NO934653L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det er beskrevet anvendelsen av stoffer som er i stand til å inhibere aktiviteten av oppløselig og fibrin- og cellebundet trombin, spesielt hirudin, dets derivater, peptider avledet derfra og trombininhibitorer av lav raolekylvekt i en fremgangsmåte for fremstilling av et farmasøyt ikum for inhlberingen av okkular fibrindan- nelse og ¿avsetning.There is disclosed the use of substances capable of inhibiting the activity of soluble and fibrin- and cell-bound thrombin, particularly hirudin, its derivatives, peptides derived therefrom, and low molecular weight thrombin inhibitors in a process for the preparation of a pharmaceutical medium for the inhibition of ocular fibrin formation and ¿deposition.

NO934653A 1992-12-17 1993-12-16 Use of thrombin inhibitors for inhibition of ocular fibrin formation NO934653L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4242655A DE4242655A1 (en) 1992-12-17 1992-12-17 Use of thrombin inhibitors to inhibit ocular fibrin formation

Publications (1)

Publication Number Publication Date
NO934653L true NO934653L (en) 1994-06-20

Family

ID=6475561

Family Applications (2)

Application Number Title Priority Date Filing Date
NO934653D NO934653D0 (en) 1992-12-17 1993-12-16 Use of thrombin inhibitors for inhibition of ocular fibrin formation
NO934653A NO934653L (en) 1992-12-17 1993-12-16 Use of thrombin inhibitors for inhibition of ocular fibrin formation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO934653D NO934653D0 (en) 1992-12-17 1993-12-16 Use of thrombin inhibitors for inhibition of ocular fibrin formation

Country Status (7)

Country Link
EP (1) EP0603112A1 (en)
JP (1) JPH06228006A (en)
KR (1) KR940013532A (en)
AU (1) AU675090B2 (en)
CA (1) CA2111644A1 (en)
DE (1) DE4242655A1 (en)
NO (2) NO934653D0 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510369A (en) * 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
US5629324A (en) * 1995-04-10 1997-05-13 Merck & Co., Inc. Thrombin inhibitors
US5798377A (en) * 1996-10-21 1998-08-25 Merck & Co., Inc. Thrombin inhibitors
WO2001070273A1 (en) * 2000-03-20 2001-09-27 Knoll Gmbh The use of anticoagulant agents in the extracorporeal treatment of blood
AU2002230836A1 (en) 2000-12-18 2002-07-01 Merck & Co., Inc. Benzylamine derivatives and their use as thrombin inhibitors
US6528503B2 (en) 2000-12-18 2003-03-04 Merck & Co., Inc. Thrombin inhibitors
US7144899B2 (en) 2001-02-09 2006-12-05 Merck & Co., Inc. Thrombin inhibitors
US7084134B2 (en) 2002-05-02 2006-08-01 Merk & Co., Inc. Thrombin inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8203887D0 (en) * 1982-06-23 1982-06-23 Kabivitrum Ab NEW TROMBIN INHIBITIVE ASSOCIATIONS
DE3445532A1 (en) * 1984-12-13 1986-06-19 Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn HIRUDIN-PA, DESULFATOHIRUDINE-PA, METHOD FOR PRODUCTION AND PHARMACEUTICAL AGENTS THAT CONTAIN THESE ACTIVE SUBSTANCES
GB8504025D0 (en) * 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
PT84170B (en) * 1986-01-24 1989-03-30 Sanofi Sa N-ALPHA-ARIL-SULFONYLAMINOACYL D-AMIDINEFENYL-ALANINAMID D NON-SUBSTITUTED DERIVATIVES PROCESS FOR THE PREPARATION OF N ALPHA-SUBSTITUTED DERIVATIVES
NL8902454A (en) * 1989-10-03 1991-05-01 Stichting Centraal Lab MUTANTS OF THE HUMANE PLASMINOGENIC ACTIVATOR INHIBITOR 1 (PAI-1), THEIR PREPARATION AND USE, AND RECOMBINANT POLYNUCLEOTIDES INCLUDING GENETIC INFORMATION CODING FOR THESE MUTANTS.
TW201303B (en) * 1990-07-05 1993-03-01 Hoffmann La Roche
DE4111394A1 (en) * 1991-04-09 1992-10-15 Behringwerke Ag AMIDINOPHENYLALANINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AND MEANS THEREOF

Also Published As

Publication number Publication date
NO934653D0 (en) 1993-12-16
EP0603112A1 (en) 1994-06-22
KR940013532A (en) 1994-07-15
DE4242655A1 (en) 1994-06-23
JPH06228006A (en) 1994-08-16
AU5243693A (en) 1994-06-30
AU675090B2 (en) 1997-01-23
CA2111644A1 (en) 1994-06-18

Similar Documents

Publication Publication Date Title
MD1507G2 (en) Inhibitors, pharmaceutical composition on base thereof and process for HIV protease inhibition
NO933239L (en)
CA2080223A1 (en) Thiophene sulfonamides useful as carbonic anhydrase inhibitors
NO932620L (en) Amindiol protease inhibitors
WO1992012717A3 (en) A composition containing a tetracycline and use for inhibiting angiogenesis
AU4787496A (en) Coating for bio-material insertable into the bloodstream or tissue of the human body
CA2264901A1 (en) Association of no syntase inhibitors with trappers of oxygen reactive forms
SE9704870D0 (en) New pharmaceutical formulation I
YU63699A (en) Compositions for treating and preventing arterial thrombosis and use of a factor xa inhibitor on its own and/or combined with a platelet antiaggregating agent
IL139967A (en) Beta-alanine derivatives and pharmaceutical compositions containing the same
ATE252885T1 (en) PLAN FOR ADMINISTRATION OF H+, K+-ATPASE INHIBITORS
NO934653L (en) Use of thrombin inhibitors for inhibition of ocular fibrin formation
IL124883A0 (en) Amidino protease inhibitors and pharmaceutical compositions containing the same
MX9800408A (en) Cyclo-oxygenase inhibitor and amidine derivative salts, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing said salts.
NO911956L (en) PROCEDURE FOR THE PREPARATION OF OXYDANT SENSITIVE AND INSENSITIVE, AROMATIC ESTERS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS
NO983295D0 (en) Control of healing process
AU1023497A (en) Tissue factor - kunitz domain fusion proteins as factor viia inhibitors
DE69625505D1 (en) GUANIDINO PROTEIASE INHIBITORS
WO2002008222A3 (en) HETEROARYL-β-ALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS
EE04044B1 (en) Pharmaceutical products for the treatment and prevention of diseases caused by vascular endothelial cell damage
AU9221898A (en) Pharmaceutical coating composition and method of use
TW340849B (en) Novel cyclopeptides and pharmaceutical compositions as integrin inhibitors comprizing the same
NO885472D0 (en) PROCEDURE FOR THE COATING OF ARTICLES OF STEEL.
RU98115584A (en) REGULATION OF THE HEALING PROCESS
CA2237335A1 (en) The use of cholinesterase inhibitors in the treatment of xerostomia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application